Rebetron

Rebetron®

Virology An antiviral that combines Rebetol®–ribavirin and Intron® A–recombinant IFN alfa-2b injection for treating chronic HCV in Pts with compensated liver disease. See Hepatitis C virus, Interferon.
References in periodicals archive ?
Impact of a designated hepatology nurse on the clinical course and quality of life of patients treated with rebetron therapy for chronic hepatitis C.
veterans' experience with rebetron in a nonstudy environment: success or failure?
Interferons such as Roferon-A, Intron-A, and Rebetron, used to boost immune response
7% Protocol follows standards approved by the department TEXAS Yes Unknown Determined by university providers UTAH Yes Unknown Inmates may apply for inter- feron review and treatment if they meet established prison criteria; A and B immuniza- tions are given to all hepatitis C-reactive inmates VERMONT VIRGINIA No 5% Drug therapy for those who meet established criteria WASHINGTON Yes 17% Typically given rebetron but will use interferon for those who meet specific criteria WEST VIRGINIA WISCONSIN Yes 13.
He successfully completed a course of rebetron and ribavirin and was cleared for renal transplant.
Schering-Plough's United States alpha interferon products include INTRON A (interferon alfa-2b, recombinant) Injection; PEG-INTRON (peginterferon alfa-2b) Powder for Injection; and REBETRON Combination Therapy containing REBETOL (ribavirin, USP) Capsules and INTRON A.
These earnings reflect the successful launch of the new combination of PEG-Intron-Rebetol in the US and Europe and the launch of Rebetron combination treatment in Japan by our partner, Schering-Plough," said Johnson Y.
The FDA encourages health care providers to report pregnancies in women on Rebetol or the sexual partners of men on Rebetol to the Rebetron Pregnancy Registry at 800-727-7064.
Schering-Plough has reported it will continue to market REBETRON Combination Therapy in the United States.
Manufactured by Schering-Plough Corporation, Rebetron is a combination of the drugs Rebetol (ribavirin), a capsule, and Intron (interferon alpha-2b recombinant), an injection.
Schering-Plough Corporation, Madison, NJ, announced the US Food and Drug Administration (FDA) has approved Rebetron Combination Therapy containing Rebetol (ribavirin, USP) capsules and Intron A (interferon alfa-2b, recombinant) injection for the treatment of hepatitis C in patients with compensated liver disease previously untreated with alpha interferon therapy.
Under his stewardship, Schering Labs created and developed important prescription therapeutic markets ranging from non-sedating antihistamines (Claritin and Clarinex) to the successful treatment of Hepatitis-C (Intron-A, Rebetron, and Peg-Intron).